Literature DB >> 17459511

Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy.

P Sharma1, B C Sharma, V Puri, S K Sarin.   

Abstract

BACKGROUND/AIMS: Minimal hepatic encephalopathy (MHE) is associated with poorer quality of life and increased work disability. Diagnosis requires cumbersome psychometric and neurophysiological tests. We evaluated critical flicker frequency (CFF) to diagnose MHE.
METHODS: 156 cirrhotic patients (age 41+/-12.5 yr) without overt encephalopathy (Child A 63, Child B 56, Child C 37) were evaluated by psychometric (number connection tests A, B or figure connection tests A, B), P300 auditory event related potential (ERP) and CFF. MHE was diagnosed by abnormal psychometric and/or P300 auditory event related potential.
RESULTS: Prevalence of MHE was 53% with 27 (43%) in Child's A, 33 (59%) in Child's B and 23 (62%) in Child's C cirrhosis (p=NS). Of 83 patients, 72 (87%) had abnormal psychometry, 64 (77%) had abnormal P300 auditory event related potential (ERP) (380.6+/-28.8 ms) and in 66 (80%) CFF was below 39 Hz. 60 (83%) patients with abnormal psychometry and 51 (80%) with abnormal P300 auditory event related potential had CFF below 39 Hz. CFF sensitivity (96%), specificity (77%) and positive predictive value (68%), negative predictive value (98%) and diagnosis accuracy was 83.3% when compared to patients with both abnormal psychometry and P300ERP.
CONCLUSIONS: Critical flicker frequency is a simple, reliable and accurate test without any age or literacy dependence for the diagnosis of MHE.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17459511     DOI: 10.1016/j.jhep.2007.02.022

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  46 in total

1.  Canadian regulations and legal ramifications for hepatic encephalopathy: a descriptive analysis.

Authors:  Henry H Nguyen; Mark G Swain; Philip Wong; Stephen E Congly
Journal:  CMAJ Open       Date:  2018-12-03

Review 2.  Advances in the evaluation and management of minimal hepatic encephalopathy.

Authors:  Jennifer Y Montgomery; Jasmohan S Bajaj
Journal:  Curr Gastroenterol Rep       Date:  2011-02

3.  Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver.

Authors:  Radha K Dhiman; Roshan Kurmi; Kiran K Thumburu; Sunil H Venkataramarao; Ritesh Agarwal; Ajay Duseja; Yogesh Chawla
Journal:  Dig Dis Sci       Date:  2010-05-28       Impact factor: 3.199

Review 4.  Advances in psychometric tests for screening minimal hepatic encephalopathy: From paper-and-pencil to computer-aided assessment.

Authors:  Ming Luo; Ping Ma; Lei Li; Wu-Kui Cao
Journal:  Turk J Gastroenterol       Date:  2019-05       Impact factor: 1.852

Review 5.  Current and future diagnosis of hepatic encephalopathy.

Authors:  Jasmohan S Bajaj
Journal:  Metab Brain Dis       Date:  2010-03-06       Impact factor: 3.584

6.  Sleep disturbances in patients of liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy.

Authors:  Jatinderpal Singh; Barjesh Chander Sharma; Vinod Puri; Sanjeev Sachdeva; Siddharth Srivastava
Journal:  Metab Brain Dis       Date:  2017-01-09       Impact factor: 3.584

7.  Treatment options for covert hepatic encephalopathy.

Authors:  Nisheet Waghray; Abhijeet Waghray; Kevin Mullen
Journal:  Curr Treat Options Gastroenterol       Date:  2014-06

8.  Intracortical inhibitory and excitatory circuits in subjects with minimal hepatic encephalopathy: a TMS study.

Authors:  Raffaele Nardone; Pierpaolo De Blasi; Yvonne Höller; Francesco Brigo; Stefan Golaszewski; Vanessa N Frey; Andrea Orioli; Eugen Trinka
Journal:  Metab Brain Dis       Date:  2016-06-02       Impact factor: 3.584

9.  Driving Performance Among Patients with Cirrhosis Who Drove to Their Outpatient Hepatology Clinic Appointments.

Authors:  Paul J Thuluvath; Anantha Nuthalapati; Jennifer Price; Anurag Maheshwari
Journal:  J Clin Exp Hepatol       Date:  2015-10-03

10.  Current trends in the treatment of hepatic encephalopathy.

Authors:  Mohamad Rasm Al Sibae; Brendan M McGuire
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.